Caris Life Sciences, Inc. (CAI) Stock: Price, Forecast & Analyst Target
Caris Life Sciences, Inc. (CAI) — MoonshotScore 91/100 (Exceptional band), calculated Oct 26, 2026. Price $32.23 (+0.70%), as of the Oct 26, 2026 trading session; market cap $9.14B. Expected results Nov 4, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.52× (market value Oct 26, 2026; cash Jun 30, 2026) · expected results Nov 4, 2026
Caris Life Sciences, Inc. · CAI · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Caris Life Sciences pairs molecular biology with machine learning to profile cancer samples for oncologists and biopharmaceutical developers. Because the underlying diagnostic volume requires continuous capital deployment into laboratory infrastructure and marketing, the investment case rests on whether cash generation from established tissue and blood tests can outpace the cash drain of launching new diagnostic panels.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Caris Life Sciences (CAI)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, though the balance sheet is only decent; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $264M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 5 of 8
- Altman Z 7.66 · Piotroski F 5
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 91 | Exceptional | |
| 83 | Exceptional | |
| 91 | Exceptional |
The score moved from 90 in the stored Oct 24, 2026 snapshot to 91 in the current publication computed Oct 26, 2026 (+1); the largest pillar moves were Financial Safety +1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $32.23 |
| Change on the day | +0.70% |
| 52-week range | $14.19–$32.89 |
| Market capitalisation | $9.14B |
| Price / earnings (trailing) | 86.04 |
| Shares traded on the day | 1.24M |
| Beta (volatility vs the S&P 500) | 0.68 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to expect clinical therapy selection volume to grow approximately 20%, with Q3 expected to hit that market continuing to improve from there. And we now expect GAAP operating expenses of $595 million to $600 million, up from $590 million to $595 million, and that is due to continued commercial expansion along with increased marketing behind our launches.
Luke Power · Statement from
And then from a CapEx standpoint, our expectation is to be in that $15 million to $20 million in Q3.
Luke Power · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Caris Life Sciences (CAI): Bullish Lean
66/100 · B+Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens, Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the CAI film — every key number, told as a short cinematic story
~2 min · open the film
What is Caris Life Sciences (CAI), and what does it report?
Short answer · as of
The company operates as a diagnostic testing and health data enterprise, analyzing tumor tissue and blood samples to match patients with targeted therapies.
Research dated 2026-09-13.
The company operates as a diagnostic testing and health data enterprise, analyzing tumor tissue and blood samples to match patients with targeted therapies. While classified broadly as a biotechnology firm, Caris functions closer to a specialized laboratory and data vendor.
Revenue tracks the volume of tests processed and the research insights sold to drug developers. The income statement reflects high fixed costs for sequencing technology and laboratory staff, meaning profit margins expand rapidly only after test volumes cross the breakeven threshold.
What do the latest results show for Caris Life Sciences (CAI)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $264M.
Research dated 2026-09-13.
Recent earnings show a distinct shift toward sustained operating cash flow generation following historical periods of severe cash burn. Revenue growth drove this transition, pushing gross profits high enough to absorb expansive research and administrative expenses.
Management credits clinical therapy selection volumes for the expanding top line and notes that further sales force expansion will keep operating expenses elevated. The fundamental mechanism is operating leverage: selling incremental tests on the same fixed laboratory base allows cash flow to break into positive territory even as marketing spend increases.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $263.71M Jun 30, 2026
- Latest quarter · R&D
- $32.36M Jun 30, 2026
- Latest quarter · SG&A
- $120.31M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $26.93M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $263.71M | $32.36M | $120.31M | $26.93M |
| Mar 31, 2026 | $216.17M | $5.37M | $104.75M | $5.28M |
| Dec 31, 2025 | $292.89M | $31.84M | $100.66M | $88.41M |
| Sep 30, 2025 | $216.83M | $21.62M | $93.24M | $32.64M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $263.71M Aug 5, 2026
- Latest report · revenue estimate
- $238.11M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $263.71M | $238.11M | −$0.0023 | $0.0059 |
| May 7, 2026 | $216.17M | $209.42M | −$0.0018 | −$0.0200 |
| Feb 26, 2026 | $292.89M | $209.54M | $0.2800 | $0.0100 |
| Nov 5, 2025 | $216.83M | $174.05M | $0.0800 | −$0.0800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $264M | -$637,000 | -$0.0023 (diluted) |
| Q1 FY2026 | $216M | -$510,000 | -$0.0018 (diluted) |
| Q4 FY2025 | $293M | $82M | $0.28 (diluted) |
| Q3 FY2025 | $217M | $24M | $0.08 (diluted) |
What are the financial strengths and risks for Caris Life Sciences (CAI)?
Short answer
Cash and short-term investments were $793.12M at the Jun 30, 2026 balance-sheet date. Operating cash flow was $61.35M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The balance sheet holds cash and liquid investments well in excess of total debt, providing a thick liquidity cushion against operational missteps. Short-term liquidity ratios show ample coverage for near-term obligations, and positive trailing cash flows mean the business funds its regular operations without needing external capital.
The clearest threat to this stability is the heavy capital expenditure required to validate and launch new assays like Caris Detect. If the upcoming pipeline fails to secure clinical adoption, the inventory and validation costs would immediately drag free cash flow back below breakeven.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $61.35M Jun 30, 2026
- Previous quarter · operating cash flow
- $32.88M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $61.35M | −$32.42M |
| Mar 31, 2026 | $32.88M | −$10.34M |
| Dec 31, 2025 | $44.78M | −$5.09M |
| Sep 30, 2025 | $62.43M | −$7.09M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Caris Life Sciences (CAI)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026.
Research dated 2026-09-13.
The immediate focal point is the anticipated commercial rollout of Caris Detect and its impact on capital expenditures. Leadership expects to fund the necessary inventory ramp using cash generated from preceding periods, maintaining free cash flow positivity for the full fiscal cycle.
Readers should monitor the upcoming earnings report to verify whether diagnostic testing volume maintains its growth trajectory and if the launch costs remain within the projected operating expense ceiling. A spike in capital spending without matching revenue gains would indicate a struggling product rollout.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We continue to expect clinical therapy selection volume to grow approximately 20%, with Q3 expected to hit that market continuing to improve from there. And we now expect GAAP operating expenses of $595 million to $600 million, up from $590 million to $595 million, and that is due to continued commercial expansion along with increased marketing behind our launches.
Luke Power ·
And then from a CapEx standpoint, our expectation is to be in that $15 million to $20 million in Q3.
Luke Power ·
So we will finish the validation and be looking to launch it this -- the back half of this year.
David Spetzler ·
And for free cash flow, we expect that to be positive for the full year as we plan to utilize the positive free cash flow from the first half of the year to fund the ramp in inventory and initiatives for Caris Detect in Q3 and then have positive free cash flow again in Q4, resulting in full year free cash flow positivity.
Luke Power ·
How does Caris Life Sciences compare with its peers?
Short answer
Caris Life Sciences's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Traditional diagnostic laboratories compete on sheer throughput of routine tests, whereas this firm focuses entirely on complex molecular profiling powered by machine learning algorithms. Instead of just delivering raw lab results, the operation packages genomic data into actionable therapeutic insights for both clinical oncologists and pharmaceutical researchers.
This parallel market approach allows the business to monetize the same laboratory infrastructure across different customer bases: billing the initial patient test and selling aggregated profiling data to drug developers hunting for novel cancer targets.
| Company | Price | Market value | Score |
|---|---|---|---|
| $313.66 Oct 26, 2026 | $9.26B | 98 5-pillar Oct 26, 2026 | |
| $308.30 Oct 26, 2026 | $6.05B | 96 5-pillar Oct 26, 2026 | |
| $72.69 Oct 26, 2026 | $11.4B | 93 5-pillar Oct 26, 2026 | |
| Caris Life Sciences (CAI) — this page | $32.23 | $9.14B | 91 |
| $87.13 Oct 26, 2026 | $9.33B | 86 5-pillar Oct 26, 2026 | |
| $140.32 Oct 26, 2026 | $8.96B | 75 5-pillar Oct 26, 2026 | |
| $143.35 Oct 26, 2026 | $5.77B | 68 5-pillar Oct 26, 2026 | |
| $54.79 Oct 26, 2026 | $8.29B | 67 5-pillar Oct 26, 2026 | |
| $55.75 Oct 26, 2026 | $10.8B | 66 5-pillar Oct 26, 2026 | |
| $44.44 Oct 26, 2026 | $7.32B | 66 5-pillar Oct 26, 2026 | |
| $137.39 Oct 26, 2026 | $5.80B | 66 5-pillar Oct 26, 2026 | |
| $86.50 Oct 26, 2026 | $7.55B | 53 5-pillar Oct 26, 2026 | |
| $205.70 Oct 26, 2026 | $13.9B | 40 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $22.00 – $33.00
- Consensus target
- $27.25
- Median target
- $27.00
Consensus record · Captured .
Measured against a quoted price of $32.23 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026
- Transactions
- 28
- Identified insiders
- 15
- Purchases
- 2
- Sales
- 5
- Other transactions
- 21
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 54.6% Period end Jun 30, 2026
- Previous quarter · ownership
- 55.5% Prior to period end Jun 30, 2026
- Reporting holders
- 257 Period end Jun 30, 2026
- Previous quarter · holders
- 208 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 30,923,878 |
| J. H. Whitney Equity Partners Vi, LLC | 11,256,615 |
| Coatue Management LLC | 9,819,992 |
| Braidwell LP | 8,256,032 |
| Sixth Street Partners Management Company, L.P. | 7,327,041 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Caris Life Sciences (CAI)?
Caris Life Sciences Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Caris fund the development of new molecular profiling tests?
The company leans on cash generated from established clinical testing volumes to finance the validation and inventory requirements of new products like Caris Detect. Its substantial liquidity reserves and newly positive operating cash flows allow management to absorb elevated research expenses without issuing new debt.
Why are gross margins expanding for these tissue and blood assays?
Processing cancer samples requires significant fixed laboratory infrastructure, meaning each additional test processed drops directly to the gross profit line. As diagnostic test volumes climb, the revenue comfortably outpaces the baseline facility costs, pushing margins upward and generating the cash needed to fund corporate expansion.
How does the commercial expansion for Caris Detect affect operating expenses?
Leadership attributes rising administrative costs to aggressive marketing campaigns supporting newly launched clinical tools. The strategy relies on spending heavily to capture market share among oncologists, betting that sustained testing volume will eventually overwhelm the near-term marketing burdens.
Why do institutional investors hold a controlling stake in this specific molecular profiling model?
Major investment funds maintain their positions because the core business is successfully shifting from deep unprofitability into positive cash generation. The concentrated fund ownership reflects market appetite for the combined revenue streams of direct patient diagnostics and pharmaceutical research support.
What is the CAI stock price today?
The last price recorded on this page for Caris Life Sciences, Inc. (CAI) is $32.23, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CAI price target?
The analyst consensus price target for Caris Life Sciences, Inc. (CAI) is $27.25 (range $22.00 to $33.00, median $27.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (82 figures)
The 82 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Luke Power (Aug 5, 2026): We continue to expect clinical therapy selection volume to grow approximately 20%, with Q3 expected to hit that market continuing to improve from there. And we now expect GAAP operating expenses of $595 million to $600 million, up from $590 million to $595 million, and that is due to continued commercial expansion along with increased marketing behind our launches. Luke Power (Aug 5, 2026): And then from a CapEx standpoint, our expectation is to be in that $15 million to $20 million in Q3. David Spetzler (Aug 5, 2026): So we will finish the validation and be looking to launch it this -- the back half of this year. Luke Power (Aug 5, 2026): And for free cash flow, we expect that to be positive for the full year as we plan to utilize the positive free cash flow from the first half of the year to fund the ramp in inventory and initiatives for Caris Detect in Q3 and then have positive free cash flow again in Q4, resulting in full year free cash flow positivity. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 750 W John Carpenter Freeway, Suite 800, Irving, TX, 75039 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "750 West John Carpenter Freeway, Irving, TX, 75039, US". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $32.23 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T19:24:18.492Z. | |
px.change | Change on the day | +0.70% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $9.14B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-26. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.225 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $264M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $14.19–$32.89 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 86.04 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.24M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.68 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | David Dean Halbert | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 1,846 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2020 through FY2025: FY2020 revenue $294.01M, net result $27.73M; FY2022 revenue $258.49M, net result −$320.83M; FY2023 revenue $306.13M, net result −$341.41M; FY2024 revenue $412.26M, net result −$281.89M; FY2025 revenue $812.03M, net result −$537.96M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 69.7% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $263.71M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $32.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $120.31M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $26.93M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $216.17M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $5.37M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $104.75M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $5.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $292.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $31.84M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $100.66M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $88.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $216.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $21.62M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $93.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $32.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $263.71M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $238.11M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | −$0.0023 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $0.0059 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $216.17M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $209.42M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.0018 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.revenue_actual | Revenue · reported — report date 2026-02-26 | $292.89M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.revenue_estimated | Revenue · estimate — report date 2026-02-26 | $209.54M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_actual | EPS · reported — report date 2026-02-26 | $0.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-26.eps_estimated | EPS · estimate — report date 2026-02-26 | $0.0100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $216.83M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $174.05M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | $0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | −$0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $793.12M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $61.35M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $452.40M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 15.45× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $61.35M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $32.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$32.42M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$10.34M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $44.78M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$5.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $62.43M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$7.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $22.00 – $33.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $27.25 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $27.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 28 transactions · 2 purchases, 5 sales, 21 other transactions · 15 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 54.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 55.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 257 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 208 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 30,923,878 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | J. H. Whitney Equity Partners Vi, LLC — shares in provider snapshot | 11,256,615 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Coatue Management LLC — shares in provider snapshot | 9,819,992 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Braidwell LP — shares in provider snapshot | 8,256,032 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Sixth Street Partners Management Company, L.P. — shares in provider snapshot | 7,327,041 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 7.66 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 11.52× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $793.12M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($263.71M) with the recorded estimate ($238.11M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.0023) with the recorded estimate ($0.0059) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 91 of 100 · Exceptional · pillars 92 / 60 / 36 / 90 / 95 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 90 (stored snapshot Oct 24, 2026) → 91 (current publication computed Oct 26, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-26.revenue_actual,earn.history.depth.2026-02-26.revenue_estimated,earn.history.depth.2026-02-26.eps_actual,earn.history.depth.2026-02-26.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-05 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 8071 — Services-Medical Laboratories. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash, investments and debt | Total debt: $452.40M; Liquidity basis: cash and short-term investments; Total liabilities: $637.89M; Cash and short-term investments: $793.12M; Cash and investments: $793.10M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $793.10M; Cash and short-term investments: $793.10M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Trailing twelve-month ratio set | Quick ratio: 4.88; Current ratio: 5.53; Debt to equity: 0.76; Net margin: 10.6%; Gross margin: 69.7%; Operating margin: 15.5%; Return on assets: 8.6%; Return on equity: 18.8% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-04; EPS estimate: $0.03 per share; Revenue estimate: $256.25M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Institutional ownership (13F) | Holders: 257; Quarter: 2026-06-30; Ownership: 54.5%; Holders previous quarter: 208; Ownership previous quarter: 55.5 13F filings are quarterly and lag the quarter end by up to 45 days. | 2026-06-30 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings |
| Analyst actions, most recent per firm | Captured record · 7 entries
One row per firm — the firm's most recent action in our feed. Other data vendors may carry firms ours does not. | 2026-08-06 | FMP | Financial Modeling Prep (FMP) analyst grades |
Data provided for informational purposes only.